Mahon and colleagues [20] have demonstrated that S100A4 knockdown sensitizes pancreatic cancer cells to gemcitabine treatment, in addition to activating caspases and PARP, resulting in increased apoptosis and cell cycle arrest. This evidence concerns the gene S100A4 and pancreatic neoplasm.